Literature DB >> 17445843

Analgesic tolerance to microinjection of the micro-opioid agonist DAMGO into the ventrolateral periaqueductal gray.

Paul J Meyer1, Erin N Fossum, Susan L Ingram, Michael M Morgan.   

Abstract

Repeated administration of the relatively low-efficacy micro-opioid receptor agonist morphine induces tolerance to its antinociceptive effects. High-efficacy agonists such as D-Ala2NMePhe4,Gly-ol5 (DAMGO) have been shown to be less effective at producing tolerance, suggesting that different neural mechanisms underlie tolerance to these agonists. However, the correlation between agonist efficacy and tolerance development has not been examined within the ventrolateral periaqueductal gray (vPAG), a brain area known to be crucial for the development of morphine tolerance. The current studies examined whether tolerance to DAMGO occurs within the vPAG, and whether repeated treatment with DAMGO into the vPAG alters the development of morphine tolerance. The results showed that repeated vPAG microinjections of DAMGO induced robust tolerance and cross-tolerance to morphine. Further, co-administration of a low dose of DAMGO with morphine potentiated morphine tolerance. These findings indicate that similar mechanisms underlie tolerance to morphine and DAMGO within the vPAG.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17445843      PMCID: PMC1971241          DOI: 10.1016/j.neuropharm.2007.03.002

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  40 in total

Review 1.  Opioid tolerance-in search of the holy grail.

Authors:  Brigitte L Kieffer; Christopher J Evans
Journal:  Cell       Date:  2002-03-08       Impact factor: 41.582

Review 2.  Insights into mu opioid pharmacology the role of mu opioid receptor subtypes.

Authors:  G W Pasternak
Journal:  Life Sci       Date:  2001-04-06       Impact factor: 5.037

3.  Morphine antinociceptive potency on chemical, mechanical, and thermal nociceptive tests in the rat.

Authors:  Michael M Morgan; Erin N Fossum; Brandon M Stalding; Melissa M King
Journal:  J Pain       Date:  2006-05       Impact factor: 5.820

4.  Antinociceptive tolerance revealed by cumulative intracranial microinjections of morphine into the periaqueductal gray in the rat.

Authors:  Michael M Morgan; Erin N Fossum; Carly S Levine; Susan L Ingram
Journal:  Pharmacol Biochem Behav       Date:  2006-09-18       Impact factor: 3.533

5.  Evidence for an intrinsic mechanism of antinociceptive tolerance within the ventrolateral periaqueductal gray of rats.

Authors:  D A Lane; P A Patel; M M Morgan
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

6.  Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats.

Authors:  E A Walker; A M Young
Journal:  Psychopharmacology (Berl)       Date:  2001-03-01       Impact factor: 4.530

7.  Intermittent dosing prolongs tolerance to the antinociceptive effect of morphine microinjection into the periaqueductal gray.

Authors:  Michael M Morgan; Bradley W Tierney; Susan L Ingram
Journal:  Brain Res       Date:  2005-09-21       Impact factor: 3.252

8.  mu-Opioid receptor downregulation contributes to opioid tolerance in vivo.

Authors:  K Stafford; A B Gomes; J Shen; B C Yoburn
Journal:  Pharmacol Biochem Behav       Date:  2001 May-Jun       Impact factor: 3.533

9.  Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization.

Authors:  Li He; Jamie Fong; Mark von Zastrow; Jennifer L Whistler
Journal:  Cell       Date:  2002-01-25       Impact factor: 41.582

10.  mu-Opioid receptors: Ligand-dependent activation of potassium conductance, desensitization, and internalization.

Authors:  Veronica A Alvarez; Seksiri Arttamangkul; Vu Dang; Abdallah Salem; Jennifer L Whistler; Mark Von Zastrow; David K Grandy; John T Williams
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

View more
  18 in total

1.  Extracellular signal-regulated kinase 1/2 activation counteracts morphine tolerance in the periaqueductal gray of the rat.

Authors:  Tara A Macey; Erin N Bobeck; Deborah M Hegarty; Sue A Aicher; Susan L Ingram; Michael M Morgan
Journal:  J Pharmacol Exp Ther       Date:  2009-08-14       Impact factor: 4.030

2.  Standard opioid agonists activate heteromeric opioid receptors: evidence for morphine and [d-Ala(2)-MePhe(4)-Glyol(5)]enkephalin as selective μ-δ agonists.

Authors:  Ajay S Yekkirala; Alexander E Kalyuzhny; Philip S Portoghese
Journal:  ACS Chem Neurosci       Date:  2009-11-25       Impact factor: 4.418

Review 3.  Inflammatory mediators of opioid tolerance: Implications for dependency and addiction.

Authors:  Lori N Eidson; Anne Z Murphy
Journal:  Peptides       Date:  2019-03-16       Impact factor: 3.750

4.  Lack of Antinociceptive Cross-Tolerance With Co-Administration of Morphine and Fentanyl Into the Periaqueductal Gray of Male Sprague-Dawley Rats.

Authors:  Erin N Bobeck; Shauna M Schoo; Susan L Ingram; Michael M Morgan
Journal:  J Pain       Date:  2019-03-07       Impact factor: 5.820

5.  Glutamate modulation of antinociception, but not tolerance, produced by morphine microinjection into the periaqueductal gray of the rat.

Authors:  Michael M Morgan; Erin N Bobeck; Susan L Ingram
Journal:  Brain Res       Date:  2009-08-05       Impact factor: 3.252

6.  Differential development of antinociceptive tolerance to morphine and fentanyl is not linked to efficacy in the ventrolateral periaqueductal gray of the rat.

Authors:  Erin N Bobeck; Rachel A Haseman; Dana Hong; Susan L Ingram; Michael M Morgan
Journal:  J Pain       Date:  2012-07-03       Impact factor: 5.820

7.  Ligand-biased activation of extracellular signal-regulated kinase 1/2 leads to differences in opioid induced antinociception and tolerance.

Authors:  Erin N Bobeck; Susan L Ingram; Sam M Hermes; Sue A Aicher; Michael M Morgan
Journal:  Behav Brain Res       Date:  2015-10-20       Impact factor: 3.332

8.  Contribution of dopamine receptors to periaqueductal gray-mediated antinociception.

Authors:  Paul J Meyer; Michael M Morgan; Laura B Kozell; Susan L Ingram
Journal:  Psychopharmacology (Berl)       Date:  2009-02-19       Impact factor: 4.530

9.  Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats.

Authors:  Udita Datta; Leslie K Kelley; Jason W Middleton; Nicholas W Gilpin
Journal:  Psychopharmacology (Berl)       Date:  2020-08-28       Impact factor: 4.530

10.  Chronic inflammatory pain prevents tolerance to the antinociceptive effect of morphine microinjected into the ventrolateral periaqueductal gray of the rat.

Authors:  Melissa L Mehalick; Susan L Ingram; Sue A Aicher; Michael M Morgan
Journal:  J Pain       Date:  2013-10-22       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.